Abstract:683 Background: It is helpful to predict early the response to anticancer drugs in non-resectable solid tumors. The purpose of this study is to evaluate whether circulating tumor DNA (ctDNA) helps predict prognosis in patients with non-resectable pancreatic cancer who have received first-line FFX or GnP therapy and have responded to treatment (CR, PR, SD groups) on initial imaging. Methods: A total of 61 patients with non-resectable pancreatic cancer treated with FFX (N=22) and GnP (N=39) as first-line therapy were included in the study. Before and after chemotherapy treatment (median 42 days, after two courses), KRAS-mutated ctDNA was measured using droplet digital PCR with CA19-9. We defined the Responder group as those with CR, PR, or SD other than PD on initial imaging and the molecular assessment as the change in KRAS-mutated ctDNA before and after treatment. (1) No appearance of KRAS-mutated ctDNA before and after treatment was defined as molecular negative (mNT); (2) disappearance of KRAS-mutated ctDNA or decrease in copy number after treatment was defined as molecular response (mR); (3) new appearance of KRAS-mutated ctDNA or increase in copy number after treatment was defined as molecular progressive disease (mPD). We investigated whether the increase or decrease of CA19-9 before and after treatment (Increase group, decrease group) and the molecular assessment were useful as prognostic factors in the Responder group. Results: Male: female = twenty-nine: thirty-two. There were fourteen patients in the locally advanced group and forty-seven patients in the distant metastatic group, both of whom were considered non-resectable. Thirty-eight patients received any second-line treatment. The prognosis of fourteen patients with PD on initial imaging was significantly worse than that of the Responder group (N=47) (Responder: PD=18.4: 9.2 months, p=0.000108). The molecular assessment in the responder group showed 30 patients in mNT group, 10 patients in mR group, and 7 patients in mPD group. The MST was 21.7, 13.2, and 13.2 months. In univariate analysis, increased CA19-9 (Increase group) and mPD were associated with worse prognosis (Increase: Decrease=13.6: 18.4 months, p=0.0487), (mPD: mNT+mR=13.2: 21.7 months, p=0.0194) and the only independent prognostic factor in multivariate analysis was mPD (Hazard ratio=3.005, p=0.0361). Conclusions: The prognosis of patients with molecular negative or molecular response after chemotherapy is relatively good (MST; 21.7 months), and efforts should be made to continue GnP and FFX. In contrast, the prognosis of patients with molecular progressive disease in the responder group is worse. Therefore, strict follow-up and change of anticancer drugs, including palliation, should be considered.

Prognostication by inflammation-based score in patients with locally advanced pancreatic cancer treated with chemoradiotherapy

Prognostic Value of Inflammatory and Nutritional Indexes among Advanced NSCLC Patients Receiving PD-1 Inhibitor Therapy

A Predictive Scoring System Based on Inflammatory and Tumor Markers for Gastric Cancer Patients Undergoing Curative Resection

A New Prognostic Score Based on the Systemic Inflammatory Response in Patients with Inoperable Non-Small-Cell Lung Cancer

Prognostic Significance of a Minute Amount of Ascites During Chemoradiotherapy for Locally Advanced Pancreatic Cancer

Prognostic nutritional index is superior as a predictor of prognosis among various inflammation-based prognostic scores in patients with hepatocellular carcinoma after curative resection

Inflammation‐based prognostic markers of metastatic pancreatic cancer using real‐world data in Japan: The Tokushukai REAl‐world Data (TREAD) project

The prognostic significance of inflammation-based scores in patients with ampullary carcinoma after pancreaticoduodenectomy

Prognostic value of postdiagnostic inflammation-based scores in short-term overall survival of advanced pancreatic ductal adenocarcinoma patients.

Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer

Prognostic value of neutrophil to lymphocyte ratio in patients with advanced pancreatic ductal adenocarcinoma treated with systemic chemotherapy

Early molecular assessment to predict prognosis in patients who respond to chemotherapy on initial imaging in pancreatic cancer.

A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy

A Novel Scoring System Based on Hemostatic Parameters Predicts the Prognosis of Patients with Advanced Pancreatic Cancer.

How Can We Better Predict the Prognosis of Patients with Pancreatic Cancer Undergoing Surgery Using an Immune-Nutritional Scoring System?

Neutrophil-to-Lymphocyte Ratio and Prognostic Nutritional Index Are Predictors for Overall Survival after Primary Pancreatic Resection of Pancreatic Ductal Adenocarcinoma: A Single Centre Evaluation

Performance of nutritional and inflammatory markers in patients with pancreatic cancer

Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‐small cell lung cancer treated with immunotherapy

A Novel Inflammatory-Nutritional Prognostic Scoring System for Stage III Gastric Cancer Patients With Radical Gastrectomy Followed by Adjuvant Chemotherapy

Prognostic Value of Inflammation and Nutrition-Based Scores in Non-Small Cell Lung Cancer

Prognostic Nutritional Index for Predicting the Clinical Outcomes of Patients with Gastric Cancer Who Received Immune Checkpoint Inhibitors.